Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 22 Apr 2023 13:10 CEST |
NAVAMEDIC | Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB | 20103015 Pharmaceuticals | Inside information |
| 29 Mar 2023 07:31 CEST |
NAVAMEDIC | Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million | 20103015 Pharmaceuticals | Inside information |
| 03 Mar 2023 12:58 CET |
NAVAMEDIC | Flagging notification Navamedic ASA | 20103015 Pharmaceuticals | Major shareholding notifications |
| 16 Feb 2023 12:01 CET |
NAVAMEDIC | NAVAMEDIC ASA: GRANT OF OPTIONS TO PRIMARY INSIDERS | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 16 Feb 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Q4 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 16 Feb 2023 08:00 CET |
NAVAMEDIC | Navamedic ASA: Resultater for fjerde kvartal 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 13 Feb 2023 09:00 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 4th quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Jan 2023 10:28 CET |
NAVAMEDIC | Navamedic ASA launches Modifast in Norway | 20103015 Pharmaceuticals | Ikke-informasjonspliktige pressemeldinger |
| 28 Dec 2022 16:38 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Nov 2022 10:05 CET |
NAVAMEDIC | Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 01 Nov 2022 08:00 CET |
NAVAMEDIC | Navamedic ASA: Q3 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 01 Nov 2022 08:00 CET |
NAVAMEDIC | Navamedic ASA: Resultater for tredje kvartal 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 25 Oct 2022 15:41 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 third quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Oct 2022 08:40 CEST |
NAVAMEDIC | Navamedic ASA launches ForlaxGO® - an innovative on-the-go product for the treatment of constipation | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 12 Aug 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Resultater for andre kvartal og første halvår 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 12 Aug 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Q2 and first half 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 09 Aug 2022 14:22 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 second quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 Aug 2022 14:09 CEST |
NAVAMEDIC | Navamedic ASA - Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig® | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 04 Jul 2022 19:23 CEST |
NAVAMEDIC | Navamedic ASA: Trading Update | 20103015 Pharmaceuticals | Inside information |
| 04 Jun 2022 18:39 CEST |
NAVAMEDIC | Navamedic ASA – Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 03 Jun 2022 13:21 CEST |
NAVAMEDIC | Navamedic ASA – Registration of share capital increase | 20103015 Pharmaceuticals | Total number of voting rights and capital |
| 02 Jun 2022 13:49 CEST |
NAVAMEDIC | Navamedic ASA: Minutes of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Jun 2022 16:07 CEST |
NAVAMEDIC | Navamedic ASA completes acquisition of Impolin AB and issues consideration shares | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 31 May 2022 15:53 CEST |
NAVAMEDIC | Navamedic ASA – Mandatory notification of trade by primary insider | 20103015 Pharmaceuticals | Mandatory notification of trade primary insiders |
| 31 May 2022 14:30 CEST |
NAVAMEDIC | NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 May 2022 13:20 CEST |
NAVAMEDIC | Navamedic ASA: Notice of Annual General Meeting | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 May 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Q1 2022 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 May 2022 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Resultater for første kvartal 2022 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 May 2022 08:50 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2022 first quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 May 2022 11:35 CEST |
NAVAMEDIC | Navamedic ASA acquires Impolin AB and bolsters its product portfolio | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 05 May 2022 10:20 CEST |
NAVAMEDIC | Navamedic ASA acquires Impolin AB and broadens obesity portfolio | 20103015 Pharmaceuticals | Inside information |
| 29 Apr 2022 08:01 CEST |
NAVAMEDIC | Navamedic: Annual report 2021 | 20103015 Pharmaceuticals | Annual financial and audit Reports |
| 17 Feb 2022 08:00 CET |
NAVAMEDIC | Navamedic ASA: Resultater for fjerde kvartal 2021 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 17 Feb 2022 08:00 CET |
NAVAMEDIC | Navamedic ASA: Q4 2021 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 16 Feb 2022 16:40 CET |
NAVAMEDIC | Navamedic ASA launches SmectaGO[®] - an innovative on-the-go product for treatment of diarrhea | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 14 Feb 2022 14:30 CET |
NAVAMEDIC | Navamedic ASA: Invitation to 2021 Fourth quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Dec 2021 13:35 CET |
NAVAMEDIC | Navamedic ASA: Trading Update | 20103015 Pharmaceuticals | Inside information |
| 06 Dec 2021 15:25 CET |
NAVAMEDIC | Financial calendar | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Nov 2021 08:00 CET |
NAVAMEDIC | Navamedic ASA has entered into a market making agreement with Norne Securities AS | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 Nov 2021 08:00 CET |
NAVAMEDIC | Navamedic ASA: Resultater for tredje kvartal 2021 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 04 Nov 2021 08:00 CET |
NAVAMEDIC | Navamedic ASA: Q3 2021 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 28 Oct 2021 10:58 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2021 Third quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Oct 2021 09:00 CEST |
NAVAMEDIC | Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 07 Sep 2021 15:51 CEST |
NAVAMEDIC | Navamedic ASA receives approval for conditional reimbursement for Mysimba® in Finland | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Sep 2021 11:00 CEST |
NAVAMEDIC | Navamedic to present at Pareto Securities' Healthcare Conference 2021 | 20103015 Pharmaceuticals | Non-regulatory press releases |
| 27 Aug 2021 15:14 CEST |
NAVAMEDIC | Flagging i Navamedic ASA | 20103015 Pharmaceuticals | Annen informasjonspliktig regulatorisk informasjon |
| 13 Aug 2021 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Resultater for andre kvartal og første halvår 2021 | 20103015 Pharmaceuticals | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 13 Aug 2021 08:00 CEST |
NAVAMEDIC | Navamedic ASA: Q2 and first half 2021 financial results | 20103015 Pharmaceuticals | Half yearly financial reports and audit reports/limited reviews |
| 10 Aug 2021 16:11 CEST |
NAVAMEDIC | Navamedic ASA: Invitation to 2021 Second quarter presentation | 20103015 Pharmaceuticals | Additional regulated information required to be disclosed under the laws of a Member State |